Skip to content

Study · Case report or series · n = 1 · 2021

4 results

Mycobacterium abscessus infection after facial injection of argireline: A case report.

Chen CF, Liu J, Wang SS, Yao YF, Yu B, Hu XP

World journal of clinical cases1 Mar 2021Cited by 6 (Europe PMC)

PMID33748252 (opens in a new tab)PMCIDPMC7953399 (opens in a new tab)DOI10.12998/wjcc.v9.i8.1996 (opens in a new tab)PepBankPUB-33748252
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a woman, erythema appeared at argireline injection sites after one week.

    In plain wordsIn one woman, redness appeared at argireline injection sites after one week.

    Peptide
    Argireline (acetyl hexapeptide-8)
    Outcome
    Not applicableInjection-site erythema
    Study

    n = 1

    Outcome group
    Adverse events · Skin and wound
    Studied dose
    Dose not stated · injection into forehead and templesAs given in this study (human).

    Source sentences

    Summary
    We report the case of a 45-year-old woman who received acetyl hexapeptide-8 (argireline) injections in the forehead and temples, and erythema, nodules, and abscesses appeared at the injection sites after one week.
  2. 02HumanCase report or seriesSafety outcome

    In a woman, nodules appeared at argireline injection sites after one week.

    In plain wordsIn one woman, nodules appeared at argireline injection sites after one week.

    Peptide
    Argireline (acetyl hexapeptide-8)
    Outcome
    Not applicableInjection-site nodules
    Study

    n = 1

    Outcome group
    Adverse events · Skin and wound
    Studied dose
    Dose not stated · injection into forehead and templesAs given in this study (human).

    Source sentences

    Summary
    We report the case of a 45-year-old woman who received acetyl hexapeptide-8 (argireline) injections in the forehead and temples, and erythema, nodules, and abscesses appeared at the injection sites after one week.
  3. 03HumanCase report or seriesSafety outcome

    In a woman, abscesses appeared at argireline injection sites after one week.

    In plain wordsIn one woman, abscesses appeared at argireline injection sites after one week.

    Peptide
    Argireline (acetyl hexapeptide-8)
    Outcome
    Not applicableInjection-site abscesses
    Study

    n = 1

    Outcome group
    Adverse events · Skin and wound
    Studied dose
    Dose not stated · injection into forehead and templesAs given in this study (human).

    Source sentences

    Summary
    We report the case of a 45-year-old woman who received acetyl hexapeptide-8 (argireline) injections in the forehead and temples, and erythema, nodules, and abscesses appeared at the injection sites after one week.
  4. 04HumanCase report or seriesSafety outcome

    In a woman with lesions after argireline injections, pus cultures confirmed Mycobacterium abscessus infection.

    In plain wordsIn one woman with lesions after argireline injections, cultures confirmed Mycobacterium abscessus infection.

    Peptide
    Argireline (acetyl hexapeptide-8)
    Outcome
    Not applicableMycobacterium abscessus infection
    Study

    n = 1

    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    Dose not stated · injection into forehead and templesAs given in this study (human).

    Source sentences

    Summary
    The pus specimens were examined by microbiological culture and confirmed to be positive for M. abscessus.
    1 context sentence
    Summary · context
    We report the case of a 45-year-old woman who received acetyl hexapeptide-8 (argireline) injections in the forehead and temples, and erythema, nodules, and abscesses appeared at the injection sites after one week.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.